{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:54:43Z","timestamp":1772758483798,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2002,6]]},"DOI":"10.1006\/clim.2002.5191","type":"journal-article","created":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T15:45:11Z","timestamp":1032191111000},"page":"231-242","source":"Crossref","is-referenced-by-count":68,"title":["Tumor Necrosis Factor-\u03b1 Blockade: A Novel Therapy for Rheumatic Disease"],"prefix":"10.1006","volume":"103","author":[{"given":"Joseph C.","family":"Shanahan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.William","family":"St. Clair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/clim.2002.5191_RF1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM199507203330302","article-title":"The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-dose Glucocorticoid Study Group","volume":"333","author":"Kirwan","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2002.5191_RF2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","article-title":"Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects","volume":"136","author":"Van Everdingen","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1006\/clim.2002.5191_RF3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","article-title":"The effectiveness of early treatment with \u201csecond-line\u201d antirheumatic drugs","volume":"124","author":"Van der Heide","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1006\/clim.2002.5191_RF4","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","article-title":"Comparison of combination therapy with single drug therapy in early rheumatoid arthritis: A randomized trial","volume":"353","author":"Mottonen","year":"1999","journal-title":"Lancet"},{"key":"10.1006\/clim.2002.5191_RF5","first-page":"S224","article-title":"The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone: A double-blind placebo-controlled study","volume":"43","author":"Kremer","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF6","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications","volume":"334","author":"O'Dell","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2002.5191_RF7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM199507203330301","article-title":"Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate\u2013Cyclosporine Combination Study Group","volume":"333","author":"Tugwell","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2002.5191_RF8","first-page":"449","article-title":"Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: Prolonged production of IL-1\u03b1","volume":"73","author":"Buchan","year":"1988","journal-title":"Clin. Exp. Immunol."},{"key":"10.1006\/clim.2002.5191_RF9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF\u03b1 antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"ii","author":"Brennan","year":"1989","journal-title":"Lancet"},{"key":"10.1006\/clim.2002.5191_RF10","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/eji.1830211039","article-title":"Expression of granulocyte-macrophage colony stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-\u03b1","volume":"21","author":"Haworth","year":"1991","journal-title":"Eur. J. Immunol."},{"key":"10.1006\/clim.2002.5191_RF11","first-page":"225","article-title":"Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist","volume":"6","author":"Butler","year":"1995","journal-title":"Eur. Cytokine Netw."},{"key":"10.1006\/clim.2002.5191_RF12","doi-asserted-by":"crossref","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","article-title":"Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis","volume":"89","author":"Williams","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1006\/clim.2002.5191_RF13","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1073\/pnas.89.16.7375","article-title":"Involvement of endogenous tumour necrosis factor-\u03b1 and transforming growth factor-\u03b2 during induction of collagen type II arthritis in mice","volume":"89","author":"Thorbecke","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1006\/clim.2002.5191_RF14","first-page":"510","article-title":"Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor-\u03b1 antibody or a recombinant soluble TNF receptor","volume":"77","author":"Piguet","year":"1992","journal-title":"Immunology"},{"key":"10.1006\/clim.2002.5191_RF15","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.4049\/jimmunol.151.11.6602","article-title":"Influence of a recombinant human soluble tumor necrosis factor receptor:Fc fusion protein on type II collagen-induced arthritis in mice","volume":"151","author":"Wooley","year":"1993","journal-title":"J. Immunol."},{"key":"10.1006\/clim.2002.5191_RF16","first-page":"433","article-title":"Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4","volume":"84","author":"Williams","year":"1995","journal-title":"Immunology"},{"key":"10.1006\/clim.2002.5191_RF17","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J."},{"key":"10.1006\/clim.2002.5191_RF18","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-\u03b1","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF19","first-page":"789","article-title":"Decrease in the cellularity and expression of adhesion molecules by anti-tumor necrosis factor-\u03b1 monoclonal antibody in patients with rheumatoid arthritis","volume":"40","author":"Tak","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF20","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute phase proteins following anti-TNF-\u03b1 therapy in rheumatoid arthritis","volume":"163","author":"Charles","year":"1999","journal-title":"J. Immunol."},{"key":"10.1006\/clim.2002.5191_RF21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/rheumatology\/36.6.643","article-title":"Reduction of matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients","volume":"36","author":"Brennan","year":"1997","journal-title":"Br. J. Rheumatol."},{"key":"10.1006\/clim.2002.5191_RF22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1","article-title":"Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor-\u03b1 and interleukin-1 in rheumatoid arthritis","volume":"41","author":"Paleolog","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","article-title":"Repeated therapy with monoclonal antibody to tumor necrosis factor-\u03b1 (cA2) in patients with rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1006\/clim.2002.5191_RF24","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumor necrosis factor-\u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1006\/clim.2002.5191_RF25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF26","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2002.5191_RF27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0950-3579(96)80043-4","article-title":"Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability","volume":"10","author":"Van der Heijde","year":"1996","journal-title":"Baillier's Clin. Rheumatol."},{"key":"10.1006\/clim.2002.5191_RF28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2002.5191_RF29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1006\/clim.2002.5191_RF30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor : Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2002.5191_RF31","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2002.5191_RF32","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/art.1780270902","article-title":"Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint","volume":"27","author":"Bromley","year":"1984","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF33","first-page":"17","article-title":"The erosive front: A topographic study of the junction between the pannu7s and the subchondral plate in the macerated rheumatoid metacarpal head","volume":"15","author":"Leisen","year":"1988","journal-title":"J. Rheumatol."},{"key":"10.1006\/clim.2002.5191_RF34","first-page":"943","article-title":"Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis","volume":"152","author":"Gravallese","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1006\/clim.2002.5191_RF35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P","article-title":"Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor","volume":"43","author":"Gravallese","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1083\/jcb.115.4.1179","article-title":"Vitronectin receptor has a role in bone resorption but does not mediate tight sealing zone attachment of osteoclasts to bone surface","volume":"115","author":"Laakakorpi","year":"1991","journal-title":"J. Cell Biol."},{"key":"10.1006\/clim.2002.5191_RF37","doi-asserted-by":"crossref","first-page":"16737","DOI":"10.1016\/S0021-9258(19)85479-0","article-title":"Biochemical characterization of human osteoclast integrins: Osteoclasts express \u03b1v\u03b23, \u03b12\u03b22, and \u03b1v\u03b21 integrins","volume":"268","author":"Nesbitt","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1006\/clim.2002.5191_RF38","doi-asserted-by":"crossref","first-page":"15006","DOI":"10.1016\/S0021-9258(17)36566-3","article-title":"Identification of matrix metalloproteinase 9 in rabbit osteoclasts","volume":"269","author":"Tezuka","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1006\/clim.2002.5191_RF39","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0021-9258(17)42227-7","article-title":"Molecular cloning of a possible cysteine protease predominantly expressed in osteoclasts","volume":"269","author":"Tezuka","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1006\/clim.2002.5191_RF40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/bbrc.1995.1013","article-title":"Molecular cloning of human cDNA for cathepsin K: Novel proteinase predominantly expressed in bone","volume":"206","author":"Inaoka","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1006\/clim.2002.5191_RF41","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1074\/jbc.271.21.12511","article-title":"Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts","volume":"271","author":"Drake","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1006\/clim.2002.5191_RF42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02411252","article-title":"Bone acid phosphatase: Tartrate-resistant acid phosphatase as marker of osteoclast function","volume":"34","author":"Minkin","year":"1982","journal-title":"Calcif. Tissue Int."},{"key":"10.1006\/clim.2002.5191_RF43","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1177\/34.10.3745910","article-title":"Demonstration of tartrate-resistant acid phosphatase in undecalcified, glycolmethacrylate-embedded mouse bone: A possible marker for (pre)osteoclast identification","volume":"34","author":"Van de Wijngaert","year":"1986","journal-title":"J. Histochem. Cytochem."},{"key":"10.1006\/clim.2002.5191_RF44","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/319516a0","article-title":"Stimulation of bone resorption and inhibition of bone formation by human tumour necrosis factors","volume":"319","author":"Bertolini","year":"1986","journal-title":"Nature"},{"key":"10.1006\/clim.2002.5191_RF45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/322547a0","article-title":"Tumor necrosis factor-\u03b1 stimulates resorption and inhibits synthesis of proteoglycan in cartilage","volume":"322","author":"Saklatvala","year":"1986","journal-title":"Nature"},{"key":"10.1006\/clim.2002.5191_RF46","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.162.6.2163","article-title":"Cachectin\/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts","volume":"162","author":"Dayer","year":"1985","journal-title":"J. Exp. Med."},{"key":"10.1006\/clim.2002.5191_RF47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1006\/clim.2002.5191_RF48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/bbrc.1998.9788","article-title":"RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogensis","volume":"253","author":"Nakagawa","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1006\/clim.2002.5191_RF49","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1006\/clim.2002.5191_RF50","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1006\/clim.2002.5191_RF51","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1073\/pnas.87.18.7260","article-title":"Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells","volume":"87","author":"Udegawa","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1006\/clim.2002.5191_RF52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/bbrc.1998.8586","article-title":"Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures","volume":"246","author":"Matsuzaki","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1006\/clim.2002.5191_RF53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S8756-3282(99)00162-3","article-title":"Interleukin-1-\u03b2 and tumor necrosis factor-\u03b1, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells","volume":"25","author":"Hofbauer","year":"1999","journal-title":"Bone"},{"key":"10.1006\/clim.2002.5191_RF54","doi-asserted-by":"crossref","first-page":"28890","DOI":"10.1074\/jbc.271.46.28890","article-title":"Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production","volume":"271","author":"Kimble","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1006\/clim.2002.5191_RF55","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1210\/endo.141.1.7285","article-title":"Tumor necrosis factor \u03b1 regulates \u03b1v\u03b25 integrin expression by osteoclast precursors in vitro and in vivo","volume":"141","author":"Inoue","year":"2000","journal-title":"Endocrinology"},{"key":"10.1006\/clim.2002.5191_RF56","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/jbmr.5650090720","article-title":"Carbonic anhydrase II mRNA expression in individual osteoclasts under \u201cresorbing\u201d and \u201cnonresorbing\u201d conditions","volume":"9","author":"Asotra","year":"1994","journal-title":"J. Bone Miner. Res."},{"key":"10.1006\/clim.2002.5191_RF57","first-page":"1955","article-title":"Granulocyte-macrophage colony stimulating factor reciprocally regulates \u03b1v-associated integrins on murine osteoclast precursors","volume":"12","author":"Inoue","year":"1998","journal-title":"Mol. Endocrinol."},{"key":"10.1006\/clim.2002.5191_RF58","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/endo.141.11.7739","article-title":"Inhibition of osteoblast differentiation by tumor necrosis factor-\u03b1","volume":"141","author":"Gilbert","year":"2000","journal-title":"Endocrinology"},{"key":"10.1006\/clim.2002.5191_RF59","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0022-2143(99)90201-9","article-title":"Tumor necrosis factor-\u03b1 and interleukin-1\u03b2 increase the Fas-mediated apoptosis of human osteoblasts","volume":"134","author":"Tsuboi","year":"1999","journal-title":"J. Lab. Clin. Med."},{"key":"10.1006\/clim.2002.5191_RF60","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.V96.5.1873","article-title":"Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines","volume":"96","author":"Weitzamnn","year":"2000","journal-title":"Blood"},{"key":"10.1006\/clim.2002.5191_RF61","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2002.5191_RF62","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2002.5191_RF63","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","article-title":"The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection","volume":"56","author":"Kindler","year":"1989","journal-title":"Cell"},{"key":"10.1006\/clim.2002.5191_RF64","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.4049\/jimmunol.162.6.3504","article-title":"Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection","volume":"162","author":"Bean","year":"1999","journal-title":"J. Immunol."},{"key":"10.1006\/clim.2002.5191_RF65","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1002\/eji.1830271215","article-title":"High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: Synergistic action of TNF and IFN-\u03b3 in the differentiation of protective granulomas","volume":"27","author":"Garcia","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"10.1006\/clim.2002.5191_RF66","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1128\/IAI.67.7.3571-3579.1999","article-title":"Fatal granuloma necrosis despite intact antibacterial functions in TNFRp55-deficient mice chronically infected with M","volume":"67","author":"Ehlers","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1006\/clim.2002.5191_RF67","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1128\/IAI.60.4.1279-1284.1992","article-title":"Importance of endogenous tumor necrosis factor-\u03b1 and gamma interferon in host resistance against Pneumocystis carinii infection","volume":"60","author":"Chen","year":"1992","journal-title":"Infect. Immun."},{"key":"10.1006\/clim.2002.5191_RF68","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.4049\/jimmunol.160.12.6072","article-title":"Blockade of endogenous TNF-\u03b1 exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms","volume":"160","author":"Allendoerfer","year":"1998","journal-title":"J. Immunol."},{"key":"10.1006\/clim.2002.5191_RF69","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/eji.1830250841","article-title":"Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to listeria monocytogenes and Leishmania major infections","volume":"25","author":"Garcia","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1006\/clim.2002.5191_RF70","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/364798a0","article-title":"Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes","volume":"364","author":"Rothe","year":"1993","journal-title":"Nature"},{"key":"10.1006\/clim.2002.5191_RF71","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1128\/IAI.64.8.3236-3243.1996","article-title":"Roles for tumor necrosis factor-\u03b1 and nitric oxide in resistance of rat alveolar macrophages to Legionella pneumophila","volume":"64","author":"Skerrett","year":"1996","journal-title":"Infect. Immun."},{"key":"10.1006\/clim.2002.5191_RF72","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1086\/516530","article-title":"Antibody-mediated depletion of tumor necrosis factor-\u03b1 impairs pulmonary host defenses to Legionella pneumophila","volume":"176","author":"Skerret","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1006\/clim.2002.5191_RF73","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1525-1373.2000.22420.x","article-title":"Tumor necrosis factor induces resistance to Legionella pneumophila infection","volume":"224","author":"McHugh","year":"2000","journal-title":"Exp. Biol. Med."},{"key":"10.1006\/clim.2002.5191_RF74","unstructured":"Food and Drug Administration Center for Biologics Evaluation and Research, Safety update on TNF-\u03b1 antagonists: Infliximab and etanercept, August 17, 2001."},{"key":"10.1006\/clim.2002.5191_RF75","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1084\/jem.173.3.647","article-title":"Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating cells","volume":"173","author":"Barth","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1006\/clim.2002.5191_RF76","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2002.5191_RF77","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/jir.1994.14.297","article-title":"Interleukin-6 antibodies in rheumatoid arthritis","volume":"14","author":"Wijdenes","year":"1994","journal-title":"J. Interferon Res."},{"key":"10.1006\/clim.2002.5191_RF78","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-\u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF79","doi-asserted-by":"crossref","first-page":"i65","DOI":"10.1136\/ard.58.2008.i65","article-title":"Etanercept: Therapeutic use in patients with rheumatoid arthritis","volume":"58","author":"Garrison","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"10.1006\/clim.2002.5191_RF80","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2133.2001.04089.x","article-title":"Treatment of psoriatic arthritis with anti-tumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate","volume":"144","author":"Ogilvie","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"10.1006\/clim.2002.5191_RF81","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaue-type psoriasis: A randomized trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1006\/clim.2002.5191_RF82","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial","volume":"35","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1006\/clim.2002.5191_RF83","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multi-center trial","volume":"116","author":"D'haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1006\/clim.2002.5191_RF84","first-page":"70","article-title":"Infliximab for refractory sarcoidosis","volume":"18","author":"Baughman","year":"2001","journal-title":"Sarcoidosis, Vasc. Diffuse Lung Dis."},{"key":"10.1006\/clim.2002.5191_RF85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-135-1-200107030-00010","article-title":"Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis actor-\u03b1 therapy","volume":"135","author":"Yee","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1006\/clim.2002.5191_RF86","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B","article-title":"Immunomodulatory effects of anti-tumor necrosis factor-\u03b1 therapy on synovium in spondyloarthropathy: Histologic findings in eight patients from an open-label study","volume":"44","author":"Baeten","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF87","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor-\u03b1 monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF88","first-page":"S89","article-title":"Quality of life in patients with severe ankylosing spondylitis in a placebo-controlled multicenter trial","volume":"44","author":"Brandt","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF89","first-page":"S90","article-title":"A randomized, double-blind placebo-controlled trial of etanercept in the treatment of ankylosing spondylitis","volume":"44","author":"Gorman","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF90","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","article-title":"Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease","volume":"45","author":"Smith","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF91","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","article-title":"Etanercept therapy in children with treatment-resistant uveitis","volume":"44","author":"Reiff","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF92","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","article-title":"Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF93","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sjogren's syndrome: A pilot study","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF94","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2002.5191_RF95","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1172\/JCI12724","article-title":"Severe inflammatory arthritis and lymphadenopathy in the absence of TNF","volume":"107","author":"Campbell","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1006\/clim.2002.5191_RF96","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.191.2.313","article-title":"Development of chronic inflammatory arthrotpathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice","volume":"191","author":"Horai","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1006\/clim.2002.5191_RF97","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/1529-0131(199810)41:10<1798::AID-ART11>3.0.CO;2-L","article-title":"Altered susceptibility to collagen induced arthritis in transgenic mice with aberrant expression of IL-1ra","volume":"41","author":"Ma","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF98","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.4049\/jimmunol.163.9.5049","article-title":"IL-1\u03b1-\u03b2 blockade prevents cartilage and bone destruction in murine type II collagen induced arthritis, whereas TNF-\u03b1 blockade only ameliorates joint inflammation","volume":"163","author":"Joosten","year":"1999","journal-title":"J. Immunol."},{"key":"10.1006\/clim.2002.5191_RF99","first-page":"645","article-title":"Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts","volume":"77","author":"Dayer","year":"1986","journal-title":"J. Exp. Med."},{"key":"10.1006\/clim.2002.5191_RF100","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.1780351016","article-title":"In vivo expression of stromelysin in synovium and cartilage of rabbits injected intra-articularly with interleukin-1\u03b2","volume":"35","author":"Hutchinson","year":"1992","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF101","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.4049\/jimmunol.149.4.1424","article-title":"Alpha 4\/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes","volume":"149","author":"Morales-Ducret","year":"1992","journal-title":"J. Immunol."},{"key":"10.1006\/clim.2002.5191_RF102","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1074\/jbc.275.7.4858","article-title":"Tumor necrosis factor-\u03b1 induces differentiation of and bone resorption by osteoclasts","volume":"275","author":"Azuma","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1006\/clim.2002.5191_RF103","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/excr.1998.4320","article-title":"Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts\/stromal cells","volume":"247","author":"Jimi","year":"1999","journal-title":"Exp. Cell Res."},{"key":"10.1006\/clim.2002.5191_RF104","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF105","first-page":"S213","article-title":"The ARMADA trial: A double-blind placebo-controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate","volume":"44","author":"Keystone","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1006\/clim.2002.5191_RF106","first-page":"S79","article-title":"Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis","volume":"44","author":"Schiff","year":"2001","journal-title":"Arthritis Rheum."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661602951910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661602951910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T06:20:24Z","timestamp":1680589224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661602951910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["S1521661602951910"],"URL":"https:\/\/doi.org\/10.1006\/clim.2002.5191","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}